Erythropoietin: A future therapy for failing hearts?

Heart Failure Reviews

Volumn 17, Issue 3, 2012, Pages 475-483

  Tilling, Lindsey ^a   Clapp, Brian ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Erythropoietin; Heart failure; Ischaemia; Signalling

Indexed keywords

ANTIANEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERYTHROPOIETIN; ERYTHROPOIETIN BETA; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE HEART INFARCTION; ANEMIA; BREAST METASTASIS; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC DRUG ADMINISTRATION; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; ENZYME ACTIVATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMATOCRIT; HUMAN; HYPERTENSION; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; LOW DRUG DOSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

ANEMIA; ANIMALS; ERYTHROPOIETIN; HEART FAILURE; HUMANS; SIGNAL TRANSDUCTION;

EID: 84862578545     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-011-9288-5     Document Type: Review

References (65)

1. The NHS Information Centre, National Heart Failure Audit 2010
2. Lloyd-Jones D et al (2010) Heart association heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121:e46-e215
3. de Boer RA et al (2003) The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 10:113-126
4. Go AS et al (2006) Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 113 (23):2713-2723
5. Groenveld HF et al (2008) Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52 (10):818-827
6. Bolger AP et al (2006) Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48:1225-1227
7. Okonko DO et al (2008) Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: observer-blinded trial. J Am Coll Cardiol 51:103-112
8. Toblli JE et al (2007) Intravenous iron reduces NTpro- brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50:1657-1665
9. Usmanov RI et al (2008) Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 21:236-242
10. Anker SD et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 (25): 2436-2448
11. van der Meer P et al (2008) Anemia and erythropoietin in heart failure. Heart Fail Monit 6 (1):28-33
12. Anand IS (2008) Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 52 (7):501-511
13. Jelkmann W (1998) Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 18 (8): 555-559
14. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352 (10):1011-1023
15. George J et al (2005) Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 165 (11):1304-1309
16. van der Meer P et al (2008) Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J 29 (12):1510-1515
17. Belonje AM et al (2010) Endogenous erythropoietin and outcome in heart failure. Circulation 121 (2):245-251
18. Westenbrink BD et al (2010) Bone marrow dysfunction in chronic heart failure patients. Eur J Heart Fail 12 (7):676-684
19. Hausenloy DJ, Yellon DM (2007) Preconditioning and postconditioning: United at reperfusion. Pharmacol Ther 116 (2): 173-191
20. Burger D, Xenocostas A, Feng QP (2009) Molecular basis of cardioprotection by erythropoietin. Curr Mol Pharmacol 2 (1): 56-69
21. Santhanam AV et al (2008) Activation of endothelial nitric oxide synthase is critical for erythropoietin-induced mobilization of progenitor cells. Peptides 29 (8):1451-1455
22. Aicher A et al (2003) Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nature Med 9 (11):1370-1376
23. Westenbrink BD et al (2010) Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. Cardiovasc Res 87 (1):30-39
24. Ruifrok WP et al (2008) Erythropoietin in cardiac disease: new features of an old drug. Eur J Pharmacol 585 (2-3):270-277
25. Urao N et al (2006) Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res 98 (11):1405-1413
26. Heeschen C et al (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102 (4):1340-1346
27. Cai Z et al (2003) Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108 (1):79-85
28. Moon C et al (2003) Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A 100 (20):11612-11617
29. Mihov D et al. (2009) Erythropoietin protects from reperfusioninduced myocardial injury by enhancing coronary endothelial nitric oxide production. Eur J Cardiothorac Surg 35 (5): 839-46; discussion 846
30. van der Meer P et al (2005) Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 46 (1):125-133
31. Hirata A et al (2006) Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 48 (1):176-184
32. Prunier F et al (2007) Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 292 (1): H522-H529
33. Li L et al (2006) Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 113 (4):535-543
34. Parsa CJ et al (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112 (7):999-1007
35. Bahlmann FH et al (2003) Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 64 (5):1648-1652
36. Ferrario M et al (2007) Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. Eur Heart J 28 (15):1805-1813
37. Namiuchi S et al (2005) High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 45 (9):1406-1412
38. Lipsic E et al (2006) A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 20 (2):135-141
39. Suh JW et al (2011) The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention. Int J Cardiol 149 (2):216-220
40. Voors AA et al (2010) A single dose of erythropoietin in STelevation myocardial infarction. Eur Heart J 31 (21):2593-2600
41. Ferrario M et al (2011) High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study. Int J Cardiol 147 (1):124-131 Epub 2009 Nov 10
42. Vanrenterghem Y et al (2002) Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 62:2167-2175
43. Silverberg DS et al (2001) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37 (7):1775-1780
44. Mancini DM et al (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107 (2):294-299
45. Palazzuoli A et al (2006) Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 152 (6):1096e9-1096e15
46. Ponikowski P et al (2007) Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 49 (7):753-762
47. van Veldhuisen DJ et al (2007) Randomized, double-blind, placebo- controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 28 (18):2208-2216
48. Ghali JK et al (2008) Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 117 (4):526-535
49. Parissis JT et al (2008) Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 155 (4):751e1-751e7
50. Palazzuoli A et al (2009) Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia. J Cardiovasc Pharmacol 53 (6):462-467
51. Parissis JT et al (2009) Effects of Darbepoetin Alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 103 (8):1134-1138
52. Cosyns B et al (2010) Effects of erythropoietin administration on mitral regurgitation and left ventricular remodeling in heart failure patients. Int J Cardiol 138 (3):306-307
53. Palazzuoli A et al (2011) Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome. Clin Exp Med 11 (1):43-48 Epub 2010 May 29
54. van der Meer P et al (2009) Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 95 (16): 1309-1314
55. Besarab A et al (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (9): 584-590
56. Singh AK et al (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (20):2085-2098
57. Pfeffer MA et al (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 (21): 2019-2032
58. Unger EF et al (2010) Erythropoiesis-stimulating agents-time for a re-evaluation. N Engl J Med 362 (3):189-192
59. Solomon SD et al (2010) Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363 (12): 1146-1155
60. Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4 (8):459-460
61. Ehrenreich H et al (2009) Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40 (12):e647-e656
62. van der Putten K et al (2010) Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study. J Nephrol. 23 (4):363-368
63. McMurray JJ et al (2009) Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 11 (8): 795-801
64. Lipsic E et al (2008) Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 10 (1):22-29
65. Fiordaliso F et al (2005) A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A 102 (6):2046-2051